GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » EV-to-EBITDA

Faron Pharmaceuticals Oy (LSE:FARN) EV-to-EBITDA : (As of May. 25, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Faron Pharmaceuticals Oy's enterprise value is £143.93 Mil. Faron Pharmaceuticals Oy's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00 Mil. Therefore, Faron Pharmaceuticals Oy's EV-to-EBITDA for today is .

The historical rank and industry rank for Faron Pharmaceuticals Oy's EV-to-EBITDA or its related term are showing as below:

LSE:FARN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -70.9   Med: -5.33   Max: -0.66
Current: -5.88

During the past 12 years, the highest EV-to-EBITDA of Faron Pharmaceuticals Oy was -0.66. The lowest was -70.90. And the median was -5.33.

LSE:FARN's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.67 vs LSE:FARN: -5.88

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), Faron Pharmaceuticals Oy's stock price is £1.925. Faron Pharmaceuticals Oy's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.413. Therefore, Faron Pharmaceuticals Oy's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Faron Pharmaceuticals Oy EV-to-EBITDA Historical Data

The historical data trend for Faron Pharmaceuticals Oy's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy EV-to-EBITDA Chart

Faron Pharmaceuticals Oy Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.10 -8.11 -7.95 -7.86 -8.79

Faron Pharmaceuticals Oy Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.95 - -7.86 - -8.79

Competitive Comparison of Faron Pharmaceuticals Oy's EV-to-EBITDA

For the Biotechnology subindustry, Faron Pharmaceuticals Oy's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Faron Pharmaceuticals Oy's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Faron Pharmaceuticals Oy's EV-to-EBITDA falls into.



Faron Pharmaceuticals Oy EV-to-EBITDA Calculation

Faron Pharmaceuticals Oy's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=143.926/0
=

Faron Pharmaceuticals Oy's current Enterprise Value is £143.93 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Faron Pharmaceuticals Oy's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Faron Pharmaceuticals Oy  (LSE:FARN) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Faron Pharmaceuticals Oy's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.925/-0.413
=At Loss

Faron Pharmaceuticals Oy's share price for today is £1.925.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Faron Pharmaceuticals Oy's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.413.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Faron Pharmaceuticals Oy EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Faron Pharmaceuticals Oy (LSE:FARN) Business Description

Traded in Other Exchanges
Address
Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Faron Pharmaceuticals Oy (LSE:FARN) Headlines

No Headlines